Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy.
作者信息
Matsuo Norikazu, Azuma Koichi, Sasada Tetsuro
机构信息
Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Cancer Vaccine Center, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.
出版信息
Oncotarget. 2019 Mar 8;10(20):1866-1867. doi: 10.18632/oncotarget.26749.
Abstract
摘要
相似文献
1
Assessment of soluble immune mediators as potential biomarkers during immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗期间可溶性免疫介质作为潜在生物标志物的评估。
Oncotarget. 2019 Mar 8;10(20):1866-1867. doi: 10.18632/oncotarget.26749.
2
[A Study of Biomarkers in Immuno-Oncology - Correlation between Gut Microbiome Composition and the Effects of Immune Checkpoint Inhibitors].免疫肿瘤学中的生物标志物研究——肠道微生物群组成与免疫检查点抑制剂疗效之间的相关性
Gan To Kagaku Ryoho. 2018 Sep;45(9):1234-1237.
3
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
4
Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.非小细胞肺癌中对PD-1/PD-L1免疫检查点抑制剂反应的预测生物标志物。
Lung Cancer. 2016 Sep;99:79-87. doi: 10.1016/j.lungcan.2016.06.016. Epub 2016 Jun 21.
5
Biomarkers for checkpoint inhibition in hematologic malignancies.血液恶性肿瘤中检查点抑制的生物标志物。
Semin Cancer Biol. 2018 Oct;52(Pt 2):198-206. doi: 10.1016/j.semcancer.2018.05.005. Epub 2018 Jun 18.
6
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.血管生成素-2 作为免疫检查点治疗的生物标志物和靶点。
Cancer Immunol Res. 2017 Jan;5(1):17-28. doi: 10.1158/2326-6066.CIR-16-0206. Epub 2016 Dec 21.
7
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.可溶性程序性死亡受体-1和程序性死亡配体-1：在癌症中的预测和预后意义
Oncotarget. 2017 May 31;8(57):97671-97682. doi: 10.18632/oncotarget.18311. eCollection 2017 Nov 14.
8
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.PD-1/PD-L1 检查点阻断免疫疗法中的预测生物标志物。
Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10.
9
[Immune checkpoint inhibitor therapy in advanced head and neck cancer].[晚期头颈癌的免疫检查点抑制剂治疗]
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Jan 7;52(1):67-70. doi: 10.3760/cma.j.issn.1673-0860.2017.01.015.
10
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells.PD-1/PD-L1免疫检查点的小分子抑制剂可缓解PD-L1诱导的T细胞耗竭。
Oncotarget. 2017 Aug 7;8(42):72167-72181. doi: 10.18632/oncotarget.20050. eCollection 2017 Sep 22.
引用本文的文献
1
Modulating Properties of Piroxicam, Meloxicam and Oxicam Analogues against Macrophage-Associated Chemokines in Colorectal Cancer.吡罗昔康、美洛昔康和奥昔康类似物对结直肠癌中巨噬细胞相关趋化因子的调节作用。
Molecules. 2021 Dec 5;26(23):7375. doi: 10.3390/molecules26237375.
本文引用的文献
1
Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma.可溶性CD163的血清水平可能是晚期皮肤黑色素瘤患者中纳武单抗疗效的预测标志物。
Front Oncol. 2018 Nov 19;8:530. doi: 10.3389/fonc.2018.00530. eCollection 2018.
2
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.抗 PD-1 抑制剂治疗非小细胞肺癌患者的可溶性免疫介质与肿瘤反应的相关性。
Int J Cancer. 2019 Mar 1;144(5):1170-1179. doi: 10.1002/ijc.31923. Epub 2018 Nov 12.
3
Blood Droplet-Based Cancer Diagnosis via Proteolytic Activity Measurement in Cancer Progression.基于血滴的癌症诊断：通过测量癌症进展中的蛋白水解活性
Theranostics. 2017 Jul 8;7(11):2878-2887. doi: 10.7150/thno.19358. eCollection 2017.
4
Monitoring immune-checkpoint blockade: response evaluation and biomarker development.监测免疫检查点阻断：疗效评估与生物标志物开发
Nat Rev Clin Oncol. 2017 Nov;14(11):655-668. doi: 10.1038/nrclinonc.2017.88. Epub 2017 Jun 27.
5
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.血清白细胞介素-8（IL-8）水平的变化反映并预测了抗 PD-1 治疗对黑色素瘤和非小细胞肺癌患者的疗效。
Ann Oncol. 2017 Aug 1;28(8):1988-1995. doi: 10.1093/annonc/mdx190.
6
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.血管生成素-2 作为免疫检查点治疗的生物标志物和靶点。
Cancer Immunol Res. 2017 Jan;5(1):17-28. doi: 10.1158/2326-6066.CIR-16-0206. Epub 2016 Dec 21.
7
CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer.CXCL2/MIF-CXCR2 信号通路促进髓源性抑制细胞的募集，并与膀胱癌的预后相关。
Oncogene. 2017 Apr;36(15):2095-2104. doi: 10.1038/onc.2016.367. Epub 2016 Oct 10.
8
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.阻断 CXCR2 介导的髓系来源抑制细胞向肿瘤转移可增强抗 PD-1 疗效。
Sci Transl Med. 2014 May 21;6(237):237ra67. doi: 10.1126/scitranslmed.3007974.
9
The role of tumor-associated macrophages in tumor vascularization.肿瘤相关巨噬细胞在肿瘤血管生成中的作用。
Vasc Cell. 2013 Dec 6;5(1):20. doi: 10.1186/2045-824X-5-20.
10
The tumor microenvironment at a glance.肿瘤微环境概览。
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6. doi: 10.1242/jcs.116392.
Zotero 插件